🚨NEW PAPER🚨 Huge congrats to @KamKaplanRFUMS on his first first-author data paper and @Lainey10yes on her first ever publication!! Seriously so proud of this lab always. Summary below (2-4). link.springer.com/article/10…

🚨 SAVE THE DATE 🚨 Registration opening soon at chicagosfn.org/

If you’re still around, I would love to chat about NPSs in Alzheimer’s disease and novel therapeutics for age-related mood disorders tonight! @ACNPorg #ACNP2026

This is definitely the place to be! Grateful to be back at #ACNP2026 #Bahamas #friends #colleagues 🤓😎🍸👌#allgood 😉

Closed out 2025 with 3 new publications! Proud to be a part of these collaborative teams. mdpi.com/3042-4518/3/1/2 (BZDs and dementia review) pmc.ncbi.nlm.nih.gov/article… (Lifestyle impact on the brain review) intechopen.com/online-first/… (LatinX Women in Research & Innovation)

Happening today!

. @ACNPorg panel not selected 😭😭 but I would still love to attend! Anyone have a guest slot available for a past travel awardee who is applying for membership this year? 🙏

📣 Today is a turning point in what we know about brain health. The results from the U.S. POINTER trial provide the rigorous data needed to say with confidence that healthy behaviors can meaningfully protect brain health across diverse populations in the U.S. The findings, shared for the first time today at #AAIC25, tested lifestyle programs that simultaneously targeted risk factors. The programs focused on: ✅👟Aerobic exercise ✅🧠Cognitive engagement ✅🥗Nutrition ✅🫀Health Monitoring U.S. POINTER is the largest research commitment the Association has made in its history. The landmark results are testament to our commitment to our mission. Thank you to the study participants, our community, our donors, and the staff who made these findings possible. alz.org/USPOINTERresults

If you’re at #AAIC25, come stop 🛑 by and say 👋🏻. Let’s chat about neuropsychiatric symptoms in aging, AD, and menopause. #159 exhibit hall.

I’m really glad conferences started offering races ☺️! Technically my first race in a different country. Bucket list item ✅ #AAIC25

Excited to see this work out! Combination therapy could be the future of AD treatments. Loved being a part of this study during my time in the Denny lab bridging the ketamine and AD crews. @BriKChen @DrChristineAnnD #ENDALZ alzres.biomedcentral.com/art…

We need to talk about the effects of US science funding cuts on the lives of scientists and on the future of discovery & innovation in this country. I am proud to be joining a panel led by @BioRender ft. speakers from across disciplines, career stages, and roles in science (1/3)

My favorite is the Summer lab explosion. I’m always impressed with the passion and new ideas from our summer interns and volunteers!! Thanks Tala Coffee Roasters for an awesome lab meeting space ☕️. Not pictured: My orange juice coffee combo 🤯.

Reminder: if you’re a scientist whose funding has been cut or impacted, I would love to interview you for a podcast I’m working on, to amplify your work. Reach out by DM or email! Hoping to release our first two episodes next week. Thanks to @estef_azevedo for artwork!

Each of us is a complicated web of emotions! @pixarinsideout @Lainey10yes @KamKaplanRFUMS @SashaFeshchenko #memoryengram #corememory #HappyHalloween

First @SfNtweets for the Hunsberger Lab! Go say hi and talk science with this awesome crew 👇🏻 #proudPI #RFU @Lainey10yes @KamKaplanRFUMS

Disease-modifying anti-amyloid beta treatments are becoming an essential part of neurologists’ repertoire for treating Alzheimer’s disease. Our commentary highlights the critical factors that will influence the clinical impacts of this treatment class! eneuro.org/content/11/9/ENEU…